ContraFect Future Growth
Future criteria checks 0/6
ContraFect is forecast to grow earnings at 6.2% per annum. EPS is expected to grow by 64.9% per annum.
Key information
6.2%
Earnings growth rate
64.9%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Apr 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -33 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -27 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -25 | N/A | N/A | 2 |
| 12/31/2022 | N/A | -65 | -46 | -46 | N/A |
| 9/30/2022 | N/A | -60 | -45 | -45 | N/A |
| 6/30/2022 | N/A | -48 | -46 | -46 | N/A |
| 3/31/2022 | N/A | -35 | -44 | -44 | N/A |
| 12/31/2021 | N/A | -20 | -41 | -41 | N/A |
| 9/30/2021 | N/A | -22 | -40 | -40 | N/A |
| 6/30/2021 | N/A | -14 | -37 | -37 | N/A |
| 3/31/2021 | N/A | -26 | -35 | -35 | N/A |
| 12/31/2020 | N/A | -28 | -33 | -33 | N/A |
| 9/30/2020 | N/A | -32 | -33 | -33 | N/A |
| 6/30/2020 | N/A | -41 | -29 | -29 | N/A |
| 3/31/2020 | N/A | -32 | -28 | -28 | N/A |
| 12/31/2019 | N/A | -13 | -27 | -27 | N/A |
| 9/30/2019 | N/A | 3 | -27 | -27 | N/A |
| 6/30/2019 | N/A | 4 | -29 | -29 | N/A |
| 3/31/2019 | N/A | -7 | -27 | -27 | N/A |
| 12/31/2018 | N/A | -38 | -26 | -26 | N/A |
| 9/30/2018 | N/A | -48 | -25 | -25 | N/A |
| 6/30/2018 | N/A | -46 | -25 | -25 | N/A |
| 3/31/2018 | N/A | -28 | -25 | -25 | N/A |
| 12/31/2017 | N/A | -16 | -25 | -25 | N/A |
| 9/30/2017 | N/A | -10 | -27 | -27 | N/A |
| 6/30/2017 | N/A | -19 | -29 | -29 | N/A |
| 3/31/2017 | N/A | -26 | -29 | -29 | N/A |
| 12/31/2016 | N/A | -29 | -29 | -29 | N/A |
| 9/30/2016 | N/A | -37 | N/A | -27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 22R is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 22R is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 22R is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 22R's revenue is forecast to grow faster than the German market.
High Growth Revenue: 22R is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 22R's Return on Equity is forecast to be high in 3 years time